BioNTech SE (22UA)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 78.75 |
|---|---|
| 52-week range | 68.30 – 105.70 |
| Return, 1 month / 3 months | −10.5% / −2.0% |
| Return, 1 year / 3 years | −12.5% / −8.8% |
| Trend | Below its 200-day average |
| RSI (14) | 39 |
| Volatility (1 year) | 48.5% |
| Worst drawdown (1 year) | -33.5% |
| Average daily value traded | 3.64M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BioNTech is a biotechnology company based in Mainz, Germany, that develops medicines built on messenger RNA and other technologies. It is known for an mRNA-based vaccine against the coronavirus, developed with a large pharmaceutical partner, and it also pursues individualized cancer immunotherapies and treatments for infectious diseases. Its customers are mainly healthcare systems, governments and pharmaceutical partners that distribute and administer its products around the world.
BioNTech SE trades under the code 22UA on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
BioNTech SE (22UA) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 78.75 on 23 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 403 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 12.5% and over the last three months it fell 2.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 49 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.5% | ||
| From 52-week high | -23.9% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -2.0% | ||
| 6-month return | -13.9% | ||
| 12-month return, skipping the last month | -2.3% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.5% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 3.64M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.2% |
|---|---|
| 1 month | −10.5% |
| 3 months | −2.0% |
| 6 months | −13.9% |
| 1 year | −12.5% |
| 3 years | −8.8% |
| 5 years | −65.5% |
Signals
| 50-day / 200-day average | 86.28 / 84.18 |
|---|---|
| Golden / death cross (60 days) | Golden, 33 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.83 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jun 2022 | EUR 1.8966 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.